Nevertheless, subgroup analysis revealed no significant prognostic differences between patients with and without SS (Table S3), indicating that SS itself does not explain the elevated risk associated with isolated anti‐SSA seropositivity. The gene discussed is RO60; the disease is synovial sarcoma.